Navigation Links
Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
Date:9/9/2010

Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today announced the first U.S. patient implant in the Occlusive/Stenotic Peripheral artery REvascularization StudY (OSPREY), which will evaluate the safety and efficacy of its MISAGO Peripheral Self-expanding Stent System for use in the superficial femoral artery (SFA). The procedure was performed at the Bradenton Cardiology Center in Bradenton, Florida.

A unique feature of the OSPREY clinical trial is that it will simultaneously enroll patients in the U.S. and Japan. Referred to as "Medical Device Collaborative Consultation and Review of Premarketing Applications" under the larger Harmonization by Doing (HBD) initiative, the OSPREY trial was selected as one of two projects to pilot this approach, which is intended to shorten the gap between product approvals in these two significant world healthcare markets. The pilot program is a cooperative effort led by the U.S. Food & Drug Administration, the MHLW-PMDA (Japan's regulatory bodies), Terumo Corporation based in Tokyo, Japan, and Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation.

"We are pleased to be the first U.S. center to kick off this exciting international trial to evaluate the safety and efficacy of the MISAGO Stent System for treating patients with peripheral artery disease," said Srinivas Iyengar, MD, primary operator and site Principal Investigator for the OSPREY trial. "This is a unique and exciting opportunity for myself and the Bradenton Cardiology Center to be a part of the first international initiative to streamline the regulatory process to facilitate future medical device approvals between countries."

In the U.S., OSPREY is a single-arm, multi-center, non-randomized prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the SFA. In Japan, there are two arms of the study, 50 patients receiving the MISAGO Stent System and 50 patients receiving percutaneous transluminal angioplasty (PTA).

The primary endpoints of the U.S. study are:

  • Primary stent patency rate at one year as confirmed by duplex ultrasound or angiography.
  • Freedom from major adverse events within 30 days of the procedure, which would result in target lesion revascularization, amputation of the treated limb or death.

The study will include up to 350 patients, a maximum of 250 patients in up to 30 centers in the U.S. and 100 patients in Japan. Japan received regulatory approval to begin the trial last year and has already started to enroll patients.

"Terumo Medical Corporation welcomes the Bradenton Cardiology Center into the OSPREY trial. We are not only grateful that our MISAGO Stent System was selected for the Harmonization By Doing program, but we feel privileged to be chosen as the first medical device company to embark in this important clinical initiative with two of the world's most preeminent regulatory bodies," said Juichi "Jim" Takeuchi, President and CEO, Terumo Medical Corporation. "We are proud of the MISAGO Stent System as our first PMA medical device and look forward to continuing to enroll patients into the OSPREY trial to bring this innovative peripheral artery disease treatment to the U.S. market."

The MISAGO Peripheral Self-expanding Stent System consists of a nitinol stent pre-mounted on the distal portion of a rapid-exchange delivery catheter system. The stent has three radiopaque markers located on each end of the stent to help ensure accurate placement in the lesion. The unique design distributes the dynamic superficial femoral artery stress loads throughout the stent's struts providing not only flexibility, but also durability against bending, compression, and torsion. The MISAGO Stent System features the first rapid-exchange (RX) delivery catheter for use in the SFA.

The MISAGO Stent System is manufactured in Japan by Terumo Corporation and has been available in Europe since November 2007. To date, approximately 9000 femoral-popliteal units have been sold (7500 patients treated).


'/>"/>

Contact: Robert Murphy
rmurphy@storchmurphy.com
908-276-0777
The Storch Murphy Group
Source:Eurekalert

Related biology news :

1. Developments in nanobiotechnology at UCSB point to medical applications
2. Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
3. Montana State University offers 6 new biomedical technologies for licensing
4. OSA launches new journal, Biomedical Optics Express
5. What the doctor prescribes: Customized medical-image databases
6. Scientists at University of Colorado Anschutz Medical Campus discover new fat cell
7. Symposium to explore broadening partnerships to spur medical advances for war injuries
8. ACP Medical Laboratory Evaluation program gains approval from CAP accreditation program
9. UCI receives prestigious federal research award to hasten medical advances
10. Biomedical scientist concerned about effects of oil spill on human health
11. CIMIT announces $3 million in medical research grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology: